GlaxoSmithKline officially closed its $10.6 billion acquisition of Cambridge, Massachusetts-based Nuvalent on Thursday, marking one of the largest oncology deals of 2026 and significantly reshaping the competitive landscape for targeted lung cancer therapies. The transaction, announced earlier this week, brings two high-priority late-stage candidates — zidesamtinib, a next-generation ROS1 inhibitor, and neladalkib, an ALK inhibitor — directly into GSK's growing oncology portfolio.

GSK Chief Executive Officer Emma Walmsley described the acquisition as a strategic acceleration of the company's ambition to become a leading oncology franchise. 'Nuvalent's pipeline addresses treatment-resistant non-small cell lung cancer with a precision and selectivity that complements our existing assets,' Walmsley said in a statement released Thursday morning from GSK's London headquarters. Analysts at JPMorgan and Morgan Stanley both upgraded their GSK price targets following confirmation of the deal's close, citing the near-term revenue potential of zidesamtinib in particular.

Zidesamtinib has generated considerable clinical interest following Phase 2 data showing durable responses in ROS1-positive non-small cell lung cancer patients who had progressed on first-generation inhibitors such as crizotinib. Nuvalent had been preparing a Biologics Licence Application submission to the FDA, and GSK is expected to confirm a formal NDA filing timeline within the next 30 to 60 days. Neladalkib, targeting ALK-rearranged NSCLC with improved central nervous system penetration, is similarly positioned for a near-term regulatory submission.

The deal positions GSK directly against Pfizer's Lorbrena and Roche's established ALK franchise, as well as emerging competitors in the ROS1 space. Industry observers note that the acquisition gives GSK a credible answer to investor concerns about its post-2028 revenue cliff as several older assets face patent expiry. Nuvalent's existing clinical team in Cambridge is expected to remain largely intact under a newly formed GSK oncology unit integrating both companies' research operations.

For patients with ROS1- or ALK-driven lung cancers who have exhausted first-line options, the accelerated integration signals a potentially faster path to market for next-generation targeted therapies. Thoracic oncology groups, including the International Association for the Study of Lung Cancer, welcomed the transaction, noting that competitive pressure typically shortens development timelines and broadens access to innovative treatments.